Table 1.
Basic characteristics of identified trial protocols
| Registration number | Anticipated completion | Sample size | Plasma therapy details (dose, titer, etc.) | Comparison(s) | Outcomes | ||
|---|---|---|---|---|---|---|---|
| Mortality | MOF | ICU stay | |||||
| Adult COVID-19 patients with respiratory involvement (mechanical ventilation, pneumonia, ARDS, etc.) | |||||||
| NCT04405310 | July 2020 | 80 | 250 mL of CP | Placebo | + | + | + |
| NCT04421404 | April 2021 | 30 | 250 mL of CP | Non-immune control plasma | + | − | − |
| NCT04415086 | May 2022 | 120 | 400 mL (300–600 mL) CP + SMT | 200 mL (150–300 mL) CP + SMT | + | − | − |
| SMT | |||||||
| NCT04418518 | December 2021 | 1200 | 500 mL of CP | No-CP | + | − | + |
| NCT04397757 | November 2020 | 80 | 2 units of CP | SMT | + | + | − |
| NCT04374487 | May 2021 | 100 | 200 mL of CP | SMT | + | + | − |
| NCT04428021 | December 2021 | 180 | 3 units of CP on day 1,3,5 + SMT | 3 units of standard plasma + SMT | + | + | + |
| SMT | |||||||
| NCT04356534 | June 2020 | 40 | 400 mL of CP given as 200 mL over 2 h in 2 consecutive days + SMT | SMT | + | − | + |
| NCT04393727 | October 2020 | 126 | 200 mL of CP | SMT | + | − | + |
| NCT04358783 | May 2021 | 30 | 200 mL of CP | SMT | + | − | − |
| NCT04340050 | November 2020 | 80 | 2 units of CP | SMT | + | + | − |
| NCT04385199 | August 2020 | 30 | 200 mL of CP transfusion over 3 h | SMT | − | − | + |
| NCT04385186 | December 2020 | 60 | 2 × 200 mL of CP | SMT | + | + | + |
| NCT04380935 | August 2020 | 60 | CP + SMT | SMT | + | + | + |
| Adult COVID-19 patients admitted to the intensive care unit | |||||||
| NCT04391101 | December 2021 | 231 | 2 units of CP (between 400 and 500 mL) | SMT | + | − | − |
| NCT04342182 | July 2020 | 426 | 300 mL of CP | SMT | + | − | − |
| NCT04347681 | April 2021 | 40 | 10–15 mL/kg CP daily, up to 5 days | No-plasma | + | − | + |
| NCT04381858 | September 2020 | 500 | 400 mL (2 units) of CP | Human Ig | + | + | + |
| Adult, severe COVID-19 patients | |||||||
| NCT04385043 | May 2021 | 400 | CP + SMT | SMT | + | − | − |
| NCT04403477 | October 2020 | 20 | 400 mL of CP + SMT | 200 mL of CP + SMT | + | + | + |
| SMT | |||||||
| NCT04364737 | April 2023 | 300 | 250-500 mL of CP | Placebo | + | − | + |
| NCT04346446 | May 2020 | 29 | CP + SMT | Placebo + SMT | + | + | + |
| NCT04425915 | May 2021 | 400 | 2 units of CP for 3 days + SMT | SMT | + | − | + |
| NCT04359810 | April 2021 | 105 | 200–250 mL of CP | Standard plasma | + | − | − |
| Adult, hospitalized COVID-19 patients | |||||||
| NCT04425837 | February 2021 | 236 | 400 mL of CP + SMT | SMT | + | + | + |
| NCT04345991 | June 2020 | 120 | 2 units of CP | SMT | + | − | − |
| NCT04388410 | December 2020 | 250 | 2 units of CP | Placebo | + | − | − |
| NCT04366245 | December 2021 | 72 | CP | SMT | + | + | − |
| NCT04348656 | December 2020 | 1200 | 500 mL of CP | SMT | + | − | + |
| NCT04345523 | July 2020 | 278 | CP | SMT | + | − | − |
| NCT04392414 | September 2020 | 60 | 2 units of CP in 24 h | 2 units of standard plasma in 24 h | + | − | + |
| NCT04383535 | September 2020 | 333 | 10–15 mL/kg of CP (5–10 mL/h infusion rate) | Placebo + SMT | + | + | + |
| NCT04377568 | May 2022 | 100 | 10 mL/kg (max 500 mL) of CP + SMT | SMT | + | + | + |
| NCT04395170 | June 2021 | 75 | 2 units of CP in 3 days | Anti-COVID-19 human Ig | + | − | + |
| SMT | |||||||
| NCT04344535 | August 2021 | 500 | 450–550 mL of CP | 450–550 mL of standard plasma | + | − | − |
MOF multiorgan failure, ICU intensive care unit, COVID-19 coronavirus disease 2019, ARDS acute respiratory distress syndrome, CP convalescent plasma, SMT standard medical therapy, Ig immunoglobulin